Related Experiment Video

Updated: Aug 12, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates

F M Huennekens1

  • 1Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037.

Trends in Biotechnology
|June 1, 1994
PubMed

Insights

Targeted cancer chemotherapy uses enzyme-monoclonal antibody conjugates to activate prodrugs specifically at tumor sites. This approach minimizes damage to healthy tissues, offering a promising strategy for effective cancer treatment.

Area of Science:

  • Oncology
  • Biochemistry
  • Drug Delivery

Background:

  • Selective drug delivery to tumors is a significant challenge in cancer chemotherapy.
  • Current treatments often cause damage to healthy tissues alongside tumor cells.

Purpose of the Study:

  • To explore the potential of enzyme-monoclonal antibody conjugates for targeted prodrug activation.
  • To achieve selective delivery of lethal drug levels to tumors while sparing normal tissues.

Main Methods:

  • Synthesis of specific prodrugs designed for enzymatic conversion.
  • Acquisition of enzymes and monoclonal antibodies for conjugate formation.
  • Manufacturing of enzyme-monoclonal antibody conjugates for in situ tumor targeting.

Main Results:

  • Prodrugs can be selectively converted to active drugs at tumor sites using targeted conjugates.
  • This method shows promise for enhancing therapeutic efficacy.
  • The approach allows for flexibility in experimental design and component selection.

Conclusions:

  • Enzyme-monoclonal antibody conjugate technology offers a viable strategy for targeted cancer chemotherapy.
  • This approach has the potential to significantly improve treatment outcomes by minimizing systemic toxicity.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.